Abstract
In high-grade serous or endometrioid ovarian cancers (HGOC), PARPi demonstrated benefit as maintenance therapy in relapsing BRCA-mutated and non-mutated tumors. Ovarian cancer is the leading cause of death among all gynaecological cancers in developed countries, with most patients presenting with advanced stage tumours, as defined by the spread of the disease outside the pelvis (FIGO stage III and IV). For advanced disease, complete resection of all macroscopic disease has been shown to be the single most important independent prognostic factor in advanced EOC and careful evaluation of patients prior to surgery is essential to defining the management plan.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
